All In Biotech

Free tool

FAERS Monitor: Vijoice

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215039 or its brand name (Vijoice, Alpelisib). Reports on generic versions are filed under their own applications.

Reports

1,873

Serious

1,427

76% of reports

Hospitalization

498

Death reported

236

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hyperglycaemia351
  • malignant neoplasm progression249
  • rash210
  • diarrhoea205
  • fatigue127
  • drug ineffective124
  • nausea123
  • breast cancer metastatic117
  • death117
  • metastases to bone94
  • blood glucose increased92
  • weight decreased91
  • metastases to liver88
  • decreased appetite85
  • diabetes mellitus85

Reports by year received

View as table
YearReports
20161
20175
20183
201990
2020172
2021269
2022402
2023334
2024228
2025192
2026177

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,286 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
breast cancer metastaticSignal117123.7103.713,976
hyperglycaemiaSignal351109.299.337,231
metastases to boneSignal9464.753.15,801
metastases to liverSignal8856.546.14,725
malignant neoplasm progressionSignal24927.424.46,315
diabetes mellitusSignal8512.510.2893
blood glucose increasedSignal925.54.5336
rashSignal2105.44.8766
decreased appetiteSignal854.13.3199
weight decreasedSignal913.73.0176
diarrhoeaSignal2053.63.1388
fatigue1271.81.549
nausea1231.71.540
death1171.51.322
drug ineffective1241.10.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.